Ott H
Eur J Rheumatol Inflamm. 1985;8(1):39-46.
The efficacy and tolerability of tenoxicam, given as a 20 mg tablet once daily for 24 months, were studied in two groups of patients. Group I (N = 29) with gonarthrosis and coxarthrosis, and Group II (N = 30) with lumbarthrosis. Parameters of pain were measured at each monthly and subsequent two-monthly consultations. In Group I, there was improvement in all parameters, especially nocturnal and end-of-day pain, and after 24 months pain had diminished in 82% of patients. Group II also showed improvement in all parameters, especially nocturnal pain and pain on waking, and although no patient's symptoms completely disappeared, 90% showed a clinical effect. Few side effects were observed; seven patients discontinued therapy for reasons unconnected with tenoxicam. Tenoxicam is well-suited to the long-term treatment of these degenerative diseases. The dose was sufficient to produce a beneficial effect in most cases, and even higher doses did not produce side effects.
对两组患者研究了替诺昔康(以20毫克片剂每日一次给药,持续24个月)的疗效和耐受性。第一组(N = 29)为膝关节炎和髋关节炎患者,第二组(N = 30)为腰椎病患者。在每月及随后每两个月的会诊时测量疼痛参数。在第一组中,所有参数均有改善,尤其是夜间和一天结束时的疼痛,24个月后82%的患者疼痛减轻。第二组在所有参数上也有改善,尤其是夜间疼痛和醒来时的疼痛,尽管没有患者症状完全消失,但90%有临床效果。观察到的副作用很少;7名患者因与替诺昔康无关的原因停止治疗。替诺昔康非常适合这些退行性疾病的长期治疗。该剂量在大多数情况下足以产生有益效果,甚至更高剂量也未产生副作用。